In the CeTeG/NOA‐09 randomized phase 3 trial, for instance, combined treatment with temozolomide and CCNU resulted in a significantly prolonged median overall survival (mOS) compared to temozolomide treatment alone in newly diagnosed glioblastoma patients ≤ 70 years of age harboring the prognostically favorable methylation of the O(6)‐methylguanine‐DNA methyltransferase (MGMT) promoter [3]. The gene discussed is MGMT; the disease is glioblastoma.